Verastem Oncology's Triplet Combination Shows No Dose-Limiting Toxicities In RAMP 203 Trial

(RTTNews) - Verastem, Inc. (VSTM), Wednesday announced preliminary clinical data from RAMP 203 Phase 1/2 study, evaluating the combination of avutometinib and sotorasib plus defactinib in patients with KRAS G12C mutant advanced non-small cell lung cancer.

The company administered 960 mg of sotorasib on a daily basis, and avutometinib 3.2 mg twice-weekly plus defactinib 200 mg twice-daily in three patients whose cancer previously progressed on a G12C inhibitor.

The preliminary data showed that tumor shrank by atleast 20 percent in two patients during the initial scans. The combined therapy also demonstrated no dose-limiting toxicities in the participants.

During the pre-market hours, Verastem's stock is trading at $4.72, up 2.61 percent on the Nasdaq.